Funds to support development, human trials, and U.S. expansion efforts.
Paris-based Robeauté has raised $28 million to advance its grain-sized microrobot technology for neurosurgical applications. The round was led by Plural, Cherry Ventures, and Kindred Ventures, with contributions from LocalGlobe, Think.Health, APEX Ventures, and strategic investor Brainlab.
Transforming Neurosurgical Precision
Robeauté’s microrobots are designed to navigate the brain’s extracellular matrix along curved pathways, enabling unprecedented access to multiple sites for various medical tasks.
Key capabilities include:
- Drug delivery: Transporting molecules to precise locations.
- Electrode implantation: Supporting neuromodulation therapies.
- Biopsy and monitoring: Collecting live cell samples and real-time data through onboard sensors.
Currently in animal studies, the technology is being developed for use as a biopsy tool, with future plans for treatment and real-time neurological monitoring.
Strategic Goals and Timeline
- Human trials: Set to begin in 2026.
- U.S. expansion: Establishing operations and pursuing FDA approval.
- Regulatory milestones: U.S. approval to precede efforts in Europe.
Bertrand Duplat, co-founder and CEO of Robeauté, said:
“We’re creating microrobots that bring unparalleled access to the brain, enabling personalized, precision medicine to transform treatments and outcomes.”
Follow MEDWIRE.AI for updates on Robeauté’s innovations and the future of neurosurgical technology!
